Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

Dyne Therapeutics is a clinical-stage neuromuscular disease company with a unique platform technology called FORCE. Their pipeline includes several promising candidates targeting genetic neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy. With well-documented governance and a strong management team, as well as a solid pipeline and a high probability of success for their leading candidate Z-rostudirsen, Dyne Therapeutics shows great potential for growth in the biotech sector.

Bears say

Dyne Therapeutics is a clinical-stage neuromuscular disease company that is focused on developing targeted therapeutics for genetically driven neuromuscular diseases. Their pipeline includes therapies for diseases with limited treatment options, and their technology has shown success in delivering safe and effective outcomes. However, the company still faces risks with safety and competition in the market, but their portfolio of programs and partnerships present a strong potential for future growth.

Dyne Therapeutics (DYN) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 10 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.